Inloggad som:

COSTAR

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

COSTAR
A randomised, open-label phase 2/3 study comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone in participants with advanced nonsmall cell lung cancer who have progressed on prior anti-PD-(l)1 therapy and chemotherapy
A randomised, open-label phase 2/3 study comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone in participants with advanced nonsmall cell lung cancer who have progressed on prior anti-PD-(l)1 therapy and chemotherapy
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 2-3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2022-10-06)

Tillbaka till listan